Clinical Trial

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Protocol Amendment History 1 change
notable Trial sites expanded: 88 -> 132 locations 2026-08-05
Trial Details
NCT Number NCT06644781
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 510 participants
Start Date 2025-03-27
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-04